First Tracks Biotherapeutics is trading at $36.32, up 5.40%, during live trading, with biotech-sector strength providing relevant support; no direct company-specific catalyst was identified.
- XBI is up 2.09% in the regular session, amid industry M&A activity and anticipation of cancer data.
- The $200 million private placement was expected to close October 19, following positive ANB033 study results announced October 12; these earlier announcements do not establish today’s direct cause.